Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 1/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 3/20 | 0.38 |
| ▸ | GSK3B | P49841 | 3/20 | 0.38 |
| ▸ | TARDBP | Q13148 | 1/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.37 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24993522 | 0.83 | DPP4 (0.40) | PTGER4GSK3AGSK3BSCN10AKIF18A | |
| SCHEMBL24993358 | 0.83 | KIF18A (0.43) | PTGER4GSK3AGSK3BTARDBPSCN10A | |
| SCHEMBL6756872 | 0.82 | RBP4 (0.44) | RBP4TARDBP | |
| SCHEMBL10367486 | 0.81 | PIM2 (0.45) | RBP4TARDBP | |
| SCHEMBL22616904 | 0.79 | AR (0.44) | RBP4TARDBP | |
| SCHEMBL29533186 | 0.79 | AR (0.44) | RBP4TARDBP | |
| SCHEMBL24993520 | 0.79 | SCN10A (0.42) | PTGER4GSK3AGSK3BTARDBPSCN10A | |
| SCHEMBL24993374 | 0.79 | TARDBP (0.44) | GSK3AGSK3BTARDBPSCN10AKIF18A | |
| SCHEMBL31078509 | 0.78 | PIM2 (0.47) | RBP4 | |
| SCHEMBL4821896 | 0.78 | KMO (0.55) | RBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727549-A2 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | University of Georgia Research Foundation, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | UNIV GEORGIA (US) | 2026-04-09 | — | — | US | disclosed |
| WO-2024258900-A2 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | SUB1, PFN1, HCCS | RBP4 2018/4885PTGER4 2726/4885GSK3A 1797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.